EMA: Reflection paper on quality, non-clinical and clinical issues related to the development of recombinant adeno-associated viral vectors

The aim of this paper is to discuss quality, non-clinical and clinical issues that should be considered during the development of medicinal products derived from AAV, and to indicate requirements that might be expected the time of a market authorisation application (MAA).